Referred by a returning client, Metagenomi engaged us to help mature their storytelling, unify how the company communicates its evolution, and create investor presentation materials under a tight timeline.

We rebuilt the story around the lead program – MGX-001 – developed a focused investor presentation, and created step-by-step mechanism of action illustrations to communicate differentiation of their in vivo gene editing approach. To support consistency across future communications, we delivered a messaging guide, and a short talk track to go with the new deck.

The result is a concise, therapy-first narrative. Metagenomi now leads with patient benefit, durability, and clinical readiness – supported by a unified talk track and messaging.